Prevention of type 1 diabetes: where we are and where we are going

被引：3

作者：

Frontino, Giulio ^{[1
]}

Guercio, Nuzio S. ^{[2
]}

Scaramuzza, Andrea ^{[3
]}

D'Annunzio, Giuseppe ^{[4
]}

Toni, Sonia ^{[5
]}

Citriniti, Felice ^{[6
]}

Bonfanti, Riccardo ^{[7
]}

机构：

[1] IRCCS San Raffaele Hosp, Diabet Res Inst, Dept Pediat, Milan, Italy

[2] ASL Salerno, Santa Maria Speranza Hosp, Div Pediat, Salerno, Italy

[3] ASST Cremona, Maggiore Hosp, Div Pediat, Cremona, Italy

[4] IRCCS Ist Giannina Gaslini, Unit Endocrinol, Clin Pediat, Genoa, Italy

[5] Meyer Children Hosp, Unit Diabetol & Endocrinol, Florence, Italy

[6] Pugliese Ciaccio Hosp, Dept Pediat, Catanzaro, Italy

[7] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Diabet Res Inst, Unit Pediat Diabet,Dept Pediat, Milan, Italy

来源：

MINERVA PEDIATRICS | 2021年 / 73卷 / 06期

关键词：

Diabetes Mellitus; type; 1; Prevention and control; Pediatrics; BETA-CELL FUNCTION; MESENCHYMAL STEM-CELLS; PRESERVES C-PEPTIDE; DOUBLE-BLIND; ISLET AUTOIMMUNITY; INCREASED RISK; DIETARY INTERVENTION; INFANT FORMULA; T-CELLS; INSULIN;

D O I：

10.23736/S2724-5276.21.06529-0

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

T1D (T1D) is one of the most frequent chronic disease in children and is associated to the risk of severe acute and chronic complications. There are about 550,000 children with T1D in the world; and about 86,000 children are diagnosed with T1D every year and its incidence is ever increasing. In this narrative review we will discuss current and future perspectives in T1D prevention strategies as well as their pitfalls. It is important to remember that for the first time one drug, in particular teplizumab (antibody anti-CD3) is going to be accepted for treatment in stage 2 of type 1 diabetes mellitus. This represent the onset of a new era.

引用

页码：486 / 503

页数：18

共 50 条

[31] Where We Were and Where We Are Going
Brown, Helene
[J]. CLINICAL JOURNAL OF ONCOLOGY NURSING, 2012, 16 (06) : 555 - 556
[32] NUTRITION - WHERE ARE WE . WHERE ARE WE GOING
HARPER, AE
[J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1969, 22 (01): : 87 - &
[33] Where we are and where we're going
Falcioni, JG
[J]. MECHANICAL ENGINEERING, 2005, 127 (04) : 4 - 4
[34] Cardiovascular Disease in Children and Adolescents with Diabetes: Where Are We, and Where Are We Going?
Truong, Uyen T.
Maahs, David M.
Daniels, Stephen R.
[J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 : S11 - S21
[35] 'WHERE ARE WE, WHERE HAVE WE COME FROM, WHERE ARE WE GOING'
BOLTON, K
[J]. OVERLAND, 1991, (123): : 52 - 53
[36] WHERE WERE WE, WHERE ARE WE, WHERE ARE WE GOING, AND WHO CARES
WOOLSEY, G
[J]. INTERFACES, 1993, 23 (05) : 40 - 46
[37] Where have we been? Where are we now? Where are we going?
Aronoff, GM
[J]. CLINICAL JOURNAL OF PAIN, 1997, 13 (01): : 3 - 5
[38] Major Marketing Traditions - Where Are We, Where Are We Going, and Where We Should Be Going and Why?
Moller, Kristian
[J]. AUSTRALASIAN MARKETING JOURNAL, 2007, 15 (01): : 37 - 38
[39] Error prevention in transfusion medicine: Where we have been and where we are going
Yomtovian, R
[J]. CLINICAL CHEMISTRY, 2001, 47 (06) : S38 - S39
[40] Preexposure Prophylaxis for HIV Prevention: Where Have We Been and Where Are We Going?
Baeten, Jared M.
Haberer, Jessica E.
Liu, Albert Y.
Sista, Nirupama
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 : S122 - S129

← 1 2 3 4 5 →